Bexson Biomedical announced today that it appointed Sheldon Moberg as its new senior vice president of drug delivery.
Santa Barbara, Calif.–based Bexson said in a news release that Moberg will lead the development of its drug delivery technologies, starting with a wearable infusion device for its BB106 therapy developed in partnership with Stevanato Group.
The lead indication for Bexson’s technology is for treating moderate to severe acute pain with its proprietary ketamine formulation, BB106, and a subcutaneous wearable device — the SG EZ-be Pod, a small, wearable and programmable infusion device customized through an agreement with Stevanato Group.
Moberg is slated to work on developing the lead product while expanding Bexson’s drug delivery program to develop solutions for other drug therapies in which subcutaneous delivery and dosing control offer distinct advantages.
“After many years in this field, I look forward to joining the Bexson team as they ramp up some truly groundbreaking device and delivery programs for pain management and other indications,” Moberg said in the release. “I believe Bexson will be able to create viable solutions that not only have the potential for difficult to treat conditions, but that can also help in preventing them.”
The veteran of more than 30 years in medical device innovation most recently served as head of advanced device technologies and innovation at Amgen. Over the course of his career, he has been granted over 130 U.S. patents and his work has led to over $1.5 billion in revenue, Bexson said.
“Sheldon has a history of developing patient-centered devices that dramatically improve lives. With his help, the technology we’re developing with Stevanato Group has great potential for application beyond our non-opioid BB106 therapy for pain management,” Bexson Biomedical co-founder & CSO Jeffrey Becker said. “Sheldon’s expertise and innovations are allowing us to explore additional psychedelic and non-psychedelic therapies to help address treatment-resistant conditions.”